Ong L.T. et al. demonstrated an epigenetic regulatory mechanism suppressing the expression of the IFI16-CXCL10/11 signaling and activation of IFN response that making HER2+ BC resistant to Herceptin treatment 47. This evidence concerns the gene IFI16 and breast cancer.